Clinical trials · New York
Prostate Cancer Recurrent clinical trials in New York
We’re tracking 41 recruiting prostate cancer recurrent studies with a site in New York — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
New York, New YorkAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Shirley, New YorkAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
New York, New YorkAges 18–100 - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
New York, New YorkAges 18–100 - NCT03701581RecruitingPhase 2/Phase 3
4-aminopyridine to help erections after prostate nerve surgery
This trial tests whether a medicine called 4-aminopyridine (4AP) can help recover or protect erectile function after “nerve-sparing” prostate surgery. It’s for men with early-stage, non-spread prostate cancer who are scheduled for robotic prostate surgery and have good baseline erections.
Rochester, New YorkAges 45–75 - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Syracuse, New YorkAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Nyack, New YorkAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Buffalo, New YorkAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide for early-stage bladder cancer
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Rochester, New YorkAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Commack, New YorkAges 18 years+ - NCT05979064Recruiting
Belly fat graft for recurrent brain tumor
This study tests if a piece of your own belly fat (omentum) placed in the brain during tumor surgery can help fight recurrent glioblastoma. It is for people who are already scheduled for surgery to remove their brain tumor.
New York, New YorkAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Buffalo, New YorkAges 18 years+ - NCT07089641RecruitingPhase 1
Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
New York, New YorkAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Commack, New YorkAges 18 years+ - NCT06627751RecruitingPhase 2
Mezigdomide, Carfilzomib, and Dexamethasone for Relapsed Myeloma
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
Buffalo, New YorkAges 18 years+ - NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+
Prostate Cancer Recurrent trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting prostate cancer recurrent studies listed above.
- Memorial Sloan Kettering Cancer Center · 5 studies
- Roswell Park Comprehensive Cancer Center · 4 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Memorial Sloan Kettering Westchester · 3 studies
- Associated Med Professionals of NY · 2 studies
- Stony Brook University Medical Center · 2 studies
- University of Rochester · 2 studies
What taking part in a prostate cancer recurrent study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate Cancer Recurrent trials in other states
Common questions
- Are there prostate cancer recurrent clinical trials in New York?
- Yes. We're currently tracking 41 recruiting prostate cancer recurrent studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer recurrent study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer recurrent studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.